and/or multivitamin supplements by those clients likely to have deficiencies due to diet or lifestyle.
Although pharmacies have only recently begun offering osteoporosis screenings, community pharmacists have been providing a variety of health screening and other services for years. Available services now include blood pressure and cholesterol measurement, anticoagulation monitoring, and asthma follow-up. [15] [16] [17] For any of these services, the pharmacist who is familiar with the recent literature and current guidelines is best able to assist clients and answer prescribers' questions. In the aforementioned areas, expert guidelines provide invaluable tools for pharmacists. [18] [19] [20] [21] [22] The recently published National Osteoporosis Foundation (NOF) report "Osteoporosis: Review of the Evidence for Prevention, Diagnosis, and Treatment and Cost-Effectiveness Analysis" should prove similarly helpful, as these guidelines clearly identify individuals for whom bone mass measurement is indicated (see Table 1 ). 1 Additionally, the NOF guidelines include treatment recommendations based on bone density and risk factors. NOF recommends antiresorptive therapy for all women with T-scores < -2 or for women with T-scores < -1.5 who have any of the risk factors listed in Table 1 . The T-score is the number of standard deviations above or below the mean for the young normal reference population. Osteoporosis is defined as a T-score <-2.5. The NOF guidelines, together with NOF educational resources, constitute valuable tools for the creation of pharmacy-based osteoporosis screening programs.
Although peripheral bone density measurement devices are being used at pharmacies, senior citizen centers, and other venues, there are few published reports on programs involving their use. Therefore, it is unclear whether these programs have implemented NOF recommendations. Similarly unclear is the extent to which the pharmacy services are accepted by physicians. 11, 12 In this article we describe a pilot pharmacy-based osteoporosis screening program that used NOF guidelines and provided NOF educational materials to clients and physicians. We also report on our assessment of primary care providers' responses to this program and offer practical suggestions for pharmacists interested in providing screening and other osteoporosis-related services to patients at risk for the disease. Rural pharmacies were used in this study, as residents in rural areas may have especially limited access to bone density measurements.
Objectives
The study reported in this article had the following objectives: to assess the feasibility of establishing, in rural community pharmacies, an osteoporosis screening program based on information and resources provided by NOF and to survey primary care providers regarding the usefulness of this screening program. On the basis of our findings, we recommend strategies for pharmacists interested in working with patients at risk for osteoporosis.
Methods
We selected a convenience sample of five independent pharmacies in rural Wisconsin. Seven pharmacists and two registered nurses participated in all aspects of the program. In preparation for the study, all participants attended a half-day seminar conducted by University of Wisconsin pharmacy (MEE, NLK, PDM) and medical school faculty (NCB) to review osteoporosis epidemiology, pathophysiology, prevention, diagnosis, and therapy. Additionally, the seminar covered bone mass measurement using hipand-spine and heel instruments, and participants received hands-on training with the Peripheral Instantaneous X-Ray Imager (PIXI) (GE Lunar Corporation, Madison, Wis.), an instrument that uses DXA technology (see Figure 1 ). 23 The project was approved by the UW Health Sciences Human Subjects Committee, and all participants provided written informed consent. Permission for the project pharmacists to mea- Photo courtesy of GE Lunar Corporation sure bone mass without a physician order was provided by the State of Wisconsin Department of Health. The targeted enrollment (100 women) was based on a projected primary care provider survey response rate of 50%. We anticipated that 50 subjects would provide a reasonably narrow confidence interval (CI) for our hypothesis that 60% of primary care physicians would find the results useful (95% CI of 46%-74%). 24 One month before we began recruiting subjects, each pharmacy mailed letters to all physicians of regular pharmacy clients describing the project and soliciting their comments. No comments were received in response to this mailing. Subsequently, each pharmacy recruited its own study subjects by posting notices in the pharmacy 3 to 6 weeks before the date of the first screening. Each woman who expressed interest was asked to fill out a prescreening questionnaire, which was evaluated by the recruiting nurse or pharmacist. To simplify this pilot project, we used only the first NOF criterion for bone mass measurement and enrolled only women who were at least 65 years old. Additionally, we excluded women who had had a previous bone density test or who were receiving osteoporosis treatment. We believed that the physician would have already considered osteoporosis in such women, so that bone density testing in the pharmacy could be seen as unnecessary. Although not required by the study protocol, two pharmacies retained these questionnaires. As part of the informed consent process, each potential subject was asked whether she wished to have the results sent to her primary health care provider. Women were also asked to complete a bone health questionnaire at the time they gave consent (see Figure 2) . Enrolled subjects received an appointment to return when PIXI would be at the pharmacy. Women were neither charged nor paid for participating in the study.
We gave careful consideration to the selection of a peripheral bone density measurement device. Calcaneal bone measurements with either ultrasound or X-ray absorptiometry are correlated with measurements at axial sites, 25 and both predict fracture risk. 9, [26] [27] [28] We chose X-ray absorptiometry over ultrasound for two reasons. First, measurements with PIXI are "dry" and measurements can be made with a sock or stocking on the foot. DXA is the only calcaneal measurement technology that does not require exposure of the bare foot to a water bath or a gel, an aspect of ultrasound we felt some clients would find unappealing. Second, testing with PIXI is very rapid (30 seconds versus up to several minutes for some ultrasound units), which makes it more practical for screenings in busy community pharmacies.
PIXI is portable, requires no external shielding, runs on standard electrical current, and has a dedicated laptop computer and printer. Analysis is automated. The software selects a region of interest (ROI) within the os calcis, and the printout includes a heel image with the ROI. Bone density is expressed as an absolute quantity (grams/cm 2 ) and as relative to the reference database, i.e., the Tscore. PIXI bone mineral density (BMD) precision (%CV) reported by the manufacturer is 1.5%. 23 As part of routine quality control, each day before performing calcaneal bone mass measurements using PIXI, we scanned an aluminum heel phantom. Measurements for the phantom averaged 99.1% of its stated value of 0.553 grams/cm 2 (range, 98.2%-100.4%) for an overall precision of 0.8%. Figures 3 and 4 show PIXI bone density printouts for normal and osteoporotic women, respectively.
For each pre-enrolled and walk-in subject, the pharmacist or nurse documented that the consent form and bone health questionnaire were complete, measured left heel bone density, reviewed the printout of the bone density test with the subject, and explained how her BMD compared with measurements in the reference database. The pharmacist or nurse also advised each woman to discuss her results with her primary health care provider and gave each patient a copy of the NOF brochures Facts About Osteoporosis, Arthritis, and Osteoarthritis 29 and Stand Up to Osteoporosis. 30 Finally, the pharmacist or nurse answered clients' general questions regarding osteoporosis, calcium and vitamin D, and lifestyle issues relevant to bone health. Women had been informed during the consent process that the pharmacist or nurse would not make a diagnosis.
For each woman who agreed to this, the pharmacy sent her primary health care provider a copy of the bone density test, bone health questionnaire, NOF's Physician's Guide to Prevention and Treatment of Osteoporosis, 31 and a letter describing the study. This package included a form with the question, "Were the bone density test, the bone health questionnaire, and the Physician's Guide useful?" and a self-addressed stamped envelope. The 95% CI for the proportion of providers who found this information useful was determined using a graphical method based on the binomial distribution. 32 
Results
We enrolled a total of 133 women at five pharmacies in the study. Operation of PIXI was straightforward and convenient. Out of the 133 subjects, only one scan was inadequate, due to incorrect heel positioning. On two occasions, a cable was inadvertently disconnected and the computer had to be rebooted. No other problems were encountered in testing. Many women expressed appreciation that the test results were available so quickly and that they could leave their sock on during the test.
Although client interest in this study was high, the prescreening records retained by two of the five pharmacies indicated that only 55% of women who expressed interest were eligible (see Table  2 ), according to the study criteria. Although the recruitment notices specified women 65 years of age and older, many younger postmenopausal women asked to be enrolled. Seven women who had had their bone mass measured previously and 16 receiving hormone replacement therapy or osteoporosis treatment were excluded per the study protocol.
Neither the investigators nor the participating pharmacists provided diagnoses to patients, as this is the responsibility of a patient's primary health care provider. Nevertheless, many TOOLS FOR ADVANCING PHARMACY PRACTICE Osteoporosis Screening women asked for an interpretation or a diagnosis immediately after the measurement, and several asked repeatedly. Although we did not keep a quantitative record of these requests, it was our impression that at least three-quarters of the women asked for an interpretation of the test results. An overwhelming majority of women agreed to have their results sent to their primary health care providers. Of the 57 physicians surveyed, 24 (42%) responded. Of these, 20, or 83% (with a 95% CI of 62%-95%), found the information useful (see Table 3 ). Two of the four physicians who stated that it was not useful preferred hip-and-spine DXA measurements. No physician stated that pharmacy-based bone density testing was inappropriate or should not have been done.
After this study was completed, pharmacists in the project were asked to provide comments. A sampling of their comments follows:
It is crucial to devise methods to obtain reimbursement for bone density screening.
It is important to work out a screening protocol with a physician well before the program is started. The screening program inspired a sense of professional satisfaction. Physicians in the community had expressed interested in further pharmacy-based osteoporosis testing. Finally, one pharmacist stated he had obtained a bone density testing unit and had begun screening using NOF guidelines.
Discussion
In this study, an osteoporosis screening program was pilot-tested in five independent community pharmacies in rural Wisconsin. Client interest was high; our recruitment goal was easily met, BMD measurements were performed efficiently, and physician satisfaction was high. NOF resources were used in four ways in this project. First, the women tested were at least 65 years old, a key group NOF recommends for testing. Second, NOF criteria, including T-score and other fracture risk factors obtained by questionnaire, were used to identify those meeting NOF treatment criteria (to be described in a subsequent report). Third, subjects were given NOF educational material. Finally, each subject's health care provider was sent the NOF Physician's Guide to Osteoporosis, 31 in addition to the bone density test results and a copy of the subject's Bone Health Questionnaire. While other community pharmacies have carried out bone density testing programs, 11, 12 to our knowledge ours was the first community pharmacy program based on NOF resources and information.
A key objective of this study was to assess whether primary care providers would find the information we provided useful. We asked only whether the provider found the information as a whole useful because we felt that a long questionnaire might lower the response rate. Also, we felt that asking about the Bone Health Questionnaire and bone density test separately would not be practical, because bone density test results are best evaluated in the context of other patient risk factors. A high proportion (83%) of physicians who did respond found the material useful, and none stated that pharmacists should not carry out osteoporosis screening. Our 42% response rate is similar to that reported for other physician surveys. 33, 34 Overall, the positive physician response in this study can be viewed as encouraging to pharmacists considering development of an osteoporosis screening program.
Client interest in osteoporosis was high, as exemplified by the ease of recruitment and the fact that women who clearly did not qualify according to the recruiting notice still wanted to participate in this study. Yet, it may be helpful for pharmacists to bear in mind that, as we found, not all women who initially express interest in the service will participate. Pharmacists should also be familiar with some of the factors that could affect participation, such as scheduling conflicts. Results from the prescreening records kept at two pharmacies (Table 2) show that approximately half of the women who originally expressed interest did not take part in the study.
Peripheral bone mass measurements are useful for initial screening, rather than diagnosis or follow-up of osteoporosis. However, some women whose bone mass had previously been measured requested heel bone density testing. These requests suggest that understanding of osteoporosis monitoring is inadequate in large segments of the target population. Based on our experience, we believe women would be receptive to pharmacy-based osteoporosis screening and pharmacists are well positioned to meet an existing need for information about osteoporosis (see Appendix 1) . In this regard, pharmacists providing peripheral measurement must be aware of the phenomenon of bone mass measurement site discordance-peripheral T-scores will sometimes be different from measurements obtained at the spine and hip. 35, 36 An understanding of these differences will help pharmacists in their discussions with both patients and clinicians. Therefore, Appendix 2 provides further information about the relationships among peripheral bone density, spine and hip bone density, and fracture risk.
Each woman was clearly informed before testing, both verbally and in writing, that pharmacists would not provide a diagnosis, and they were encouraged to discuss their results with their physician, who would provide an interpretation or diagnosis. Still, approximately three-quarters of the women tested wanted an interpretation or diagnosis immediately after the test. This observation reinforces the need for pharmacists to formulate a clear-cut plan regarding what information to provide clients. For example, one might argue that a pharmacist informing a client that she has "low bone density" or "osteoporosis" based on a bone density test conducted in a pharmacy has provided a diagnosis (i.e., is practicing medicine).
Ultimately, if pharmacy-based osteoporosis screening is to improve a patient's skeletal health, the bone mass data must be translated into action. In our study, 92% of women wanted the test results sent to their physicians, and the physicians found the information useful. These findings bode well for pharmacy-based osteoporosis screening. In addition to providing the physician with objective information, the screening may foster discussions about bone health between women and their health care providers.
Comments from pharmacists in the project indicated that there was continued interest in osteoporosis screening on their part and TOOLS FOR ADVANCING PHARMACY PRACTICE Osteoporosis Screening on the part of clients and health care providers. Their comments also reflect the fact that much work is necessary to institute a successful screening program, especially where reimbursement issues are concerned. Based on our experience with this project and our examination of the literature, we developed a set of recommendations for community pharmacists who are interested in becoming further involved in the area of osteoporosis. These are provided in Appendix 3.
Limitations
The generalizability of our findings is limited, because the study used technology that requires substantial investment and, thus, may not be available to many pharmacies. Peripheral bone density instruments cost between $10,000 and $30,000. It may be impractical for one pharmacy to make such a large investment. However, sharing a unit among pharmacies may be a solution, because the units are portable and screening can be offered on a periodic basis.
We did not explore the issues of reimbursement potential, either directly from women or through third party payers.
A nonacademically based community pharmacy screening program may have some advantages over the one described here. Such a program, for example, may not require written informed consent from clients (although a liability waiver might be considered). Additionally, all NOF testing criteria could be followed, thereby broadening the range of clients eligible for screening. Because this was a pilot program, we kept the enrollment criteria simple and enrolled only women aged 65 and older. Our results suggest that, using a simpler form of the Bone Health Questionnaire, community pharmacists could readily assess women for NOF-designated risk factors so that qualified postmenopausal women under 65 could be tested. A final advantage is reimbursement: Pharmacies uninvolved in an academic research project could more readily advertise the service and charge a fee.
Conclusion
Using NOF resources, five community pharmacies in rural Wisconsin carried out a pilot osteoporosis screening program involving 133 rural postmenopausal women and using NOF resources in a number of ways. First, the women tested were 65 years of age and older, a key group NOF recommends for screening. Second, women were provided with NOF literature. Finally, each subject's primary care provider received her bone mass measurement, the results of a Bone Health Questionnaire including osteoporosis risk factors, and NOF literature. The majority of physicians who provided feedback found the information we provided useful. We conclude that osteoporosis screening carried out by community pharmacists can be well accepted by physicians, and that the recently published NOF guidelines offer community pharmacists a practical tool for osteoporosis screening.
Appendix 1. Recommendations for Pharmacists
Pharmacists can become involved in osteoporosis education in a number of ways, whether or not they carry out bone density screening in their pharmacies.
Suggestions for all pharmacists: 1. Know and recognize risk factors for osteoporosis: 1 Personal history of fracture, loss of height, kyphosis Learn the basic facts about peripheral bone density testing. Crucial to a good osteoporosis screening program, but often overlooked, are an understanding of the test results, knowledge of the strengths and weaknesses of peripheral bone density measurements, and awareness of the importance of communicating with clients' primary health care providers. Be aware that peripheral bone densitometry is an evolving area that is still hotly debated among experts. 35, 36 In choosing a device for osteoporosis screening, pharmacists should think through exactly what they will communicate to physicians and should be prepared to discuss test results with primary health care providers. Pharmacists should consider the following: 1. Primary care physicians have been shown to have a better understanding of test results and to make more appropriate clinical decisions when radiologists provided them with more complete interpretations of hip and spine DXAs instead of brief reports. 40 Although this is a very different situation from that of a pharmacist carrying out osteoporosis screening, the principle is the same: An explanatory cover letter accompanying the results of the bone density test may make the screening results much more useful to the clinician. Such a letter could include information on the technology used from the published literature and from the manufacturer of the specific device. 2. Be aware of the phenomenon of site discordance, that there is not always a good match between bone density at different skeletal sites. 35, 36 Greenspan et al. 25 examined postmenopausal women with a variety of calcaneal measurement devices and with DXA of the hip and spine. Measurements made with all tested heel measurement devices correlated reasonably well with hip bone density (correlation coefficients 0.70-0.80). The heel bone measurement units also showed a similar ability to discriminate among those individuals who were normal or osteoporotic at the hip. The authors concluded that heel measurement by either X-ray absorptiometry or ultrasound may be valuable for osteoporosis screening. A recent study examined calcaneal measurements made with a heel ultrasound unit (McCue CubaClinical Mk II) and the PIXI in comparison with lumbar spine and hip bone density with the Lunar-DPX-L. 41 The researchers found no difference in the performance of heel units for their ability to discriminate among normal elderly women and those with osteopenia or osteoporosis at the hip. Receiver operator characteristic (ROC) analysis for the identification of osteoporotic subjects was performed. Areas under the ROC curve (95% confidence intervals) for the probability that a subject would be osteoporotic were 0.814 (0.700, 0.928) for calcaneal BMD as measured by PIXI and 0.793 (0.675, 0.911) for the ultrasound unit. 41 Although the discriminatory abilities of calcaneal units are good, the pharmacist should understand that these correlations are not perfect and there are some individuals with normal bone density at the heel and osteoporosis at the hip and vice versa. 3. Be aware that low heel BMD has been shown to be predictive of hip fracture. Based on data from 8,134 ambulatory women in the Study of Osteoporotic Fractures, Cumming et al. 26 concluded that low heel bone density was correlated with hip fracture risk. Other work has shown that ultrasound measurements of the heel are also predictive of hip fracture. 27 a. Become familiar with the basic principles of peripheral bone density testing. Understand the strengths and weaknesses of peripheral bone density measurements for osteoporosis screening. b. Check with local or regional authorities regarding the permissibility of nonphysician operation of bone density measurement devices (whether X-ray or ultrasound). State health departments should be able to provide this information. c. Communicate with local prescribers before starting the program. Consider asking a physician to review the policies and plans for the program. d. Select a unit. Important items to consider are the skeletal site measured (heel, forearm, or other); the technology used (ultrasound versus X-ray), legal requirements for use (some states restrict use of X-ray units), physical specifications that will affect portability and placement of the unit, patient preparation (ultrasound requires a gel or water; DXA does not), duration of the scan (DXA may be 30 seconds, ultrasound can take minutes), cost (usually $10,000 to $30,000), and whether the unit can be used in other settings (DXA may be best in a nursing home setting, easing patient preparation and increasing patient comfort). Finally, a crucial point is interpretation of the test results. Review the published literature and information from the manufacturer regarding how well the peripheral measurement correlates to measurements at other skeletal sites and to fracture risk. e. Consider strategies for acquiring a unit: rent, buy, or buy and share the unit among pharmacies. f. Decide whom to screen ( 
